Stock Ratings / Health Care / TRLV / options

CRON (51) RGC (38) DFTX (52) TLRY (20) ⌘ Pro Terminal →

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) Options Positioning, Max Pain & Unusual Sweeps

$10.28 -3.02% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.20

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.04B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TRLV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TRLV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE: TRLV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $10.28 (-3.02% 1D, market cap $2.04B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, TRLV ranks #197 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TRLV compare to CRON and RGC in the Health Care sector?

▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TRLV carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 60.2%, and ROIC of 12.8%. By comparison, CRON (Cronos Group Inc. Common Share) holds a D grade (51/100 RQD, P/E N/A, ROIC -4.5%, cap $1.24B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, TRLV leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TRLV?

▼

Per TRLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754195), Trulieve Cannabis Corp. Subordinate Voting Shares generated $1.18B in revenue (-0.4% YoY), -$116.4M in net income, and $228.6M in free cash flow against $2.70B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.20 (-0.73%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 19.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRLV)Realized 20D OHLCV Swing Band: ±12.1%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY TRLV SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)

FRED Regime × Technicals: 65% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 19.4% FCF Margin ($228.6M FCF) & 60.2% Gross Margin

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk8/20 pts (-12 pt drag)

Balance-sheet & 10-K footnote risk deducts 12 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$10.39-1.1% Next Q

Q2 (-2Q)

Grade C+$10.28+5.3% Next Q

Q3 (-1Q)

Grade C$10.82-5% Next Q

Current

Grade D+$10.28+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TRLV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, TRLV faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 57.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($11.18) or 200D SMA ($8.83) invalidates the momentum regime and cuts Target Base ($10.28) toward Bear Floor ($8.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRLV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TRLV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (TRLV)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for TRLV.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRLV)

✓Walkthrough of TRLV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRLV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.10%▲ ASCENDING CHANNEL

2026-11-02O $10.62H $10.62L $10.28C $10.28VOL 1.03M

RES: $14.88SUP: $8.66SMA50: $11.18SMA200: $8.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRLV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRLV Butterfly Map → + Track TRLV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

3.1%/yr Implied 5Y Growth

vs. -0.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRLV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRLV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRLV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRLV)

Health Care Rank #197 of 1016 ⚔️ CRON vs TRLV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRLV vs. CRON, RGC, DFTX, TLRY)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) ranks #197 by composite RQD confidence (58/100, grade D+) and #258 by equity capitalization ($2.04B). Within this direct 5-issuer industry benchmark cohort, TRLV leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRLV ACTIVE Trulieve Cannabis Corp. Subordinate Voting Shares	D+	58/100	—	60.2%	12.8%	-3.02%	$2.04B	Benchmark Subject
CRON Cronos Group Inc. Common Share	D	51/100	—	42.8%	-4.5%	-1.79%	$1.24B	/cron-vs-trlv →
RGC Regencell Bioscience Holdings Limited	D-	38/100	—	—	—	-2.19%	$3.40B	/rgc-vs-trlv →
DFTX Definium Therapeutics Inc.	D+	52/100	—	—	-32.2%	-4.29%	$5.10B	/dftx-vs-trlv →
TLRY Tilray Brands Inc.	E	20/100	—	28.4%	-3.9%	-4.17%	$390.2M	/tlry-vs-trlv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001754195

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) reported GAAP revenue of $1.18B (-0.4% vs. FY2024 revenue of $1.19B , and +4.6% cumulative change since FY2023) , GAAP net income of -$116.4M, operating cash flow of $272.8M, and free cash flow of $228.6M (+53.6% YoY). On the balance sheet, TRLV closed FY2025 with $2.70B in total assets against $0 in total debt (Altman Z-Score: 1.12, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.18B	-$116.4M	$272.8M	$228.6M	$2.70B	—
FY2024 (FY)	2024-12-31	$1.19B	-$155.1M	$271.5M	$148.9M	$2.87B	—
FY2023 (FY)	2023-12-31	$1.13B	-$526.8M	$201.8M	$201.8M	—	—

3. TRLV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRLV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TRLV compare to CRON and RGC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TRLV?

Where is TRLV trading relative to its 50-day, 200-day, and 52-week technical levels?

TRLV last traded at $10.28 (-3.02% on volume of 1,413,944 shares), positioning the stock -8.05% below its 50-day simple moving average ($11.18) and +16.42% above its 200-day simple moving average ($8.83). Across its 52-week range of $4.62 to $13.28, TRLV sits at the 65.4% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($9.04 to $11.52).

TRLV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is TRLV's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for TRLV.

Direct Sub-Reports: TRLV RQD Cockpit TRLV 12M Forecast TRLV Earnings & Move TRLV Dividends & DRIP TRLV Insiders & 13F TRLV Whale Options TRLV Profit Sankey TRLV News & Why

ROARABLE RATING BRIEF • RQD 58/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TRLV — Trulieve Cannabis Corp. Subordinate Voting Shares: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TRLV scores 58 out of 100, a letter grade of D+, with a verdict label of "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental Cash Engine: 13 / 20. The pillar is cited with ROIC of 12.8% and FCF yield of 11.2%. Per the market data, these are the company's stronger reported return metrics, and they are the main support for this pillar.
Whale 13F Flow: 10 / 20. The pillar description references institutional accumulation and options positioning. The holder data section is empty, so the underlying 13F and options detail cannot be verified from the source data.
Insider Conviction: 12 / 20. The pillar description references SEC Form 4 and Congressional PTR cluster flow. No insider transaction records are included in the source data, so the basis for this score cannot be verified.
Macro Regime Fit: 15 / 20. Per the RQD rating, beta is 1.0, and the pillar reflects sector sensitivity. This is the highest pillar score, though it is still below the midpoint of its range.
Forensic Balance Sheet: 8 / 20. The pillar is cited with Altman Z of 1.12, Piotroski F of 6/9, and Debt/Equity of 0.5. The Altman Z reading is the weakest forensic input provided.

For a prospective investor evaluating the stock today, the combined picture is a mid-range cash-generation profile offset by weak forensic balance-sheet scores and low institutional and insider conviction scores. The verdict label indicates the rating system's view that fundamentals are weak relative to the stock's current standing. This is an analytical reading of the rating's components, not a recommendation to buy or sell.

Business

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) is a NYSE-listed issuer classified under the Health Care sector and the Medicinal Chemicals and Botanical Products industry. The source data does not describe its products, customer base, or revenue model beyond this classification. Per the company profile, the market capitalization is $2.0B. Per the SEC financials, reported revenue was $1181.2M for FY 2025.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1181.2M	$143.5M	$-116.4M	N/A	$228.6M	$255.5M	N/A
FY 2024	$1186.5M	$97.8M	$-155.1M	N/A	$148.9M	$238.8M	N/A
FY 2023	$1129.2M	$-221.6M	$-526.8M	N/A	$201.8M	N/A	N/A

Per the market data, the gross margin is 60.2%, the operating margin is 12.1%, and the net margin is -9.9%. Per the SEC financials, operating income moved from $-221.6M in FY 2023 to $97.8M in FY 2024 and $143.5M in FY 2025, while net income remained negative in all three periods. Per the Roarable RQD rating, ROIC is 12.8%, and the forensic inputs are an Altman Z-Score of 1.12, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. Reported cash was $255.5M for FY 2025 and $238.8M for FY 2024.

Open Questions

What drove the move in operating income from negative in FY 2023 to positive in FY 2024 and FY 2025, and how much of the net loss in each year reflects non-operating items?
Why are EPS, debt, and cash for FY 2023 reported as N/A or missing, and what is the company's reported debt level?
What supports the Whale 13F Flow and Insider Conviction pillar scores, given that no holder or insider transaction data is included?
What is the basis for the trailing and forward P/E being unavailable, and how should the EV/EBITDA of 9.9 be interpreted without earnings per share?
What is the company's product and revenue mix within the Medicinal Chemicals and Botanical Products industry?

TRLV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TRLV Debate Forum (3) ↓

🟢 CATALYST Benzinga • 13h ago

Trulieve Cannabis Awarded Registrations For Medical Marijuana Dispensaries From U.S. Drug Enforcement Administration

Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that Trulieve has received registrations for medical

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 10d ago

Deckers Outdoor Posts Mixed Q2 Results, Joins BayCom, Five Point Holdings And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures fell, led by Deckers down 9% after mixed results and reduced FY27 guidance. BayCom, ROLR, Trulieve and others also slid premarket.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 10d ago

Cantor Fitzgerald Reiterates Overweight on Trulieve Cannabis, Maintains $15 Price Target

Cantor Fitzgerald analyst Gabie Ingoglia reiterates Trulieve Cannabis (NYSE:TRLV) with a Overweight and maintains $15 price target.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 16d ago

3 Great Biotech Stocks To Watch In October 2026

High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of pressure often pushes investors toward higher risk, higher potential areas like biotechnology. Volatil

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 20d ago

Full Transcript: Trulieve Cannabis Q2 2026 Earnings Call

On Friday, Trulieve Cannabis (NYSE:TRLV) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial

Read Full Source ↗

🟢 CATALYST Yahoo • 21d ago

Zacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve Cannabis

ICU Medical, Neogen and Trulieve Cannabis offer distinct growth catalysts as medical products demand benefits from innovation, resilient procedures and evolving market opportunities.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TRLV Bull vs. Bear Conversation Board — What's Your Call at $10.28?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TRLV 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $11.45 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TRLV (D+ • RQD 58/100) a Buy at $10.60?

Welcome to the TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) Roar Pit. Current RQD Composite is 58/100 (Roarable Sell — Weak Fundamentals / Trim) in Medicinal Chemicals and Botanical Products. Bulls point to capital efficiency (12.8% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.27 (-22.0%)

Spot @ $10.60

Pump the brakes on TRLV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TRLV, but look at what you are paying: current EV/EBITDA multiples with 60.2% gross margins. Unless Trulieve Cannabis Corp. Subordinate Voting Shares expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.25 (+25.0%)

Spot @ $10.60

TRLV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TRLV, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $10.60 (52-wk range $4.62 - $13.28), any beat on forward guidance forces shorts and underweight funds to chase.